<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3976">
  <stage>Registered</stage>
  <submitdate>23/10/2012</submitdate>
  <approvaldate>23/10/2012</approvaldate>
  <nctid>NCT01752634</nctid>
  <trial_identification>
    <studytitle>Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis</studytitle>
    <scientifictitle>A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis</scientifictitle>
    <utrn />
    <trialacronym>FUTURE 2</trialacronym>
    <secondaryid>2012-004439-22</secondaryid>
    <secondaryid>CAIN457F2312</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriatic Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Secukinumab (AIN457)
Treatment: drugs - Placebo

Experimental: Secukinumab (AIN457) 150 mg s.c. - Group 2 - Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.

Experimental: Secukinumab (AIN457) 75 mg s.c. - Group 1- Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.

Placebo Comparator: Placebo s.c. - Group 4 - Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4

Experimental: Secukinumab (AIN457) 300 mg s.c. - Group 3 - Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4


Treatment: drugs: Secukinumab (AIN457)
Secukinumab (AIN457)

Treatment: drugs: Placebo
Placebo PFS for s.c. administration.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving American College of Rheumatology 20 (ACR20) response criteria - To demonstrate that the efficacy of PFS secukinumab at Week 24 is superior to placebo in subjects with active PsA based on the proportion of subjects achieving an American College of Rheumatology 20 (ACR20) response</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a PASI75 response in the subgroup of subjects who have =3% skin involvement with psoriasis - To demonstrate that The efficacy of secukinumab at Week 24 is superior to placebo based on the proportion of subjects achieving a PASI75 response in the subgroup of subjects who have =3% skin involvement with psoriasis</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a PASI90 response in the subgroup of subjects who have =3% skin involvement with psoriasis - To demonstrate that the efficacy of secukinumab at Week 24 is superior to placebo based on the proportion of subjects achieving a PASI90 response in the subgroup of subjects who have =3% skin involvement with psoriasis</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in DAS28-CRP - To demonstrate that the improvement (change) from baseline on secukinumab is superior to placebo for the DAS28-CRP at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in SF36-PCS - To demonstrate that the improvement (change) from baseline on secukinumab is superior to placebo for the SF36-PCS at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in HAQ-DI - To demonstrate that the improvement (change) from baseline on secukinumab is superior to placebo for the HAQ-DI at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving ACR50 response criteria - To demonstrate that the efficacy of PFS secukinumab at Week 24 is superior to placebo in subjects with active PsA based on the proportion of subjects achieving an American College of Rheumatology 50 (ACR50) response</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with dactylitis in the subset of subjects who have dactylitis at baseline - To demonstrate that the efficacy of secukinumab pooled regimen at Week 24 is superior to placebo based on the proportion of subjects with dactylitis in the subset of subjects who have dactylitis at baseline</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with enthesitis in the subset of subjects who have enthesitis at baseline - To demonstrate that the efficacy of secukinumab pooled regimen at Week 24 is superior to placebo based on the proportion of subjects with enthesitis in the subset of subjects who have enthesitis at baseline</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients eligible for inclusion in this study have to fulfill all of the
        following criteria:

          -  Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months
             with moderate to severe PsA who must have at Baseline =3 tender joints out of 78 and
             =3 swollen out of 76 (dactylitis of a digit counts as one joint each)

          -  Rheumatoid factor and anti-CCP antibodies negative at screening

          -  Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or
             documented history of plaque psoriasis

          -  Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization
             with inadequate control of symptoms or at least one dose if stopped due to intolerance
             to NSAIDs

          -  Subjects taking corticosteroids must be on a stable dose of =10 mg/day prednisone or
             equivalent for at least 2 weeks before randomization and should remain on a stable
             dose up to Week 24

          -  Subjects taking MTX (= 25 mg/week) are allowed to continue their medication if the
             dose is stable for at least 4 weeks before randomization and should remain on a stable
             dose up to Week 52.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients fulfilling any of the following criteria are not eligible for
        inclusion in this study:

          -  Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process,
             obtained within 3 months prior to screening and evaluated by a qualified physician

          -  Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone,
             morphine)

          -  Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or
             IL-17 receptor

          -  Ongoing use of prohibited psoriasis treatments / medications (e.g., topical
             corticosteroids, UV therapy) at randomization. The following wash out periods need to
             be observed:

          -  Oral or topical retinoids 4 weeks

          -  Photochemotherapy (e.g. PUVA) 4 weeks

          -  Phototherapy (UVA or UVB) 2 weeks

          -  Topical skin treatments (except in face, scalp and genital area during screening, only
             corticosteroids with mild to moderate potency) 2 weeks

          -  Subjects who have ever received biologic immunomodulating agents except for those
             targeting TNFa, investigational or approved

          -  Previous treatment with any cell-depleting therapies including but not limited to
             anti-CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3,
             anti-CD19)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>399</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,TAS,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Kogarah</hospital>
    <hospital>Novartis Investigative Site - Maroochydore</hospital>
    <hospital>Novartis Investigative Site - Hobart</hospital>
    <hospital>Novartis Investigative Site - Malvern East</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4558 - Maroochydore</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3145 - Malvern East</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hasselt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Bruntal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Herne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Zerbst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Petrozavodsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-on-Don</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Rajathevee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Staffordshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to provide 24 - 52 week efficacy, safety and tolerability data to support the
      registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self
      administration in subjects with active PsA despite current or previous NSAID, DMARD and/or
      anti-TNFa therapy. An additional 4 years of long-term efficacy and safety data will be
      collected during the post Week 52 period of the study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01752634</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>